What changed
$STE — BUY 📊
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.
🎯 Q1 FY26 | Rev $2B | EPS $2.83 vs $2.85 🔴
💡 Consensus expects flat growth and margin pressure post-miss; we see organic growth accelerating to mid-single digits and margins expanding, leading to 5-10% EPS beats over the next two quarters.
📉 Reward/Risk: 2.5:1
🏢 Business Quality: 8/10 - Wide moat from sterilization services and installed base, essential in healthcare, recurring revenue.
📊 Valuation: fair - PE 26.1x at historical median; EV/EBITDA likely ~18x; FCF yield 0.85% low but reflects growth capex; in line with medtech peers at 25-30x.
🔮 Catalyst: Next quarterly earnings report (FQ1 2027)
💰 Entry: $202, stop $190, target $225
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/STE0620
Also in play: $DELL $HPE $SMCI $NTAP $IBM $NVDA
Why it matters
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.